Evolus Inc (NASDAQ:EOLS) Director Simone Blank purchased 628,536 shares of the company’s stock in a transaction on Monday, May 20th. The shares were purchased at an average cost of $19.25 per share, for a total transaction of $12,099,318.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
NASDAQ EOLS traded down $0.01 on Wednesday, hitting $17.52. 573,342 shares of the stock were exchanged, compared to its average volume of 1,060,925. The company has a current ratio of 14.80, a quick ratio of 14.52 and a debt-to-equity ratio of 0.96. Evolus Inc has a 52 week low of $10.22 and a 52 week high of $39.50. The firm has a market capitalization of $478.87 million, a P/E ratio of -11.16 and a beta of 5.01.
Evolus (NASDAQ:EOLS) last posted its quarterly earnings results on Tuesday, April 30th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by ($0.11). On average, research analysts anticipate that Evolus Inc will post -3.06 EPS for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC bought a new stake in Evolus during the first quarter worth about $115,000. Metropolitan Life Insurance Co NY bought a new stake in Evolus during the first quarter worth about $83,000. Perceptive Advisors LLC bought a new stake in Evolus during the first quarter worth about $344,000. Morgan Stanley lifted its position in Evolus by 239.8% during the first quarter. Morgan Stanley now owns 201,708 shares of the company’s stock worth $4,552,000 after purchasing an additional 142,351 shares during the period. Finally, SEI Investments Co bought a new stake in Evolus during the first quarter worth about $416,000. Hedge funds and other institutional investors own 19.33% of the company’s stock.
EOLS has been the topic of several analyst reports. Zacks Investment Research lowered shares of Evolus from a “hold” rating to a “sell” rating in a research report on Wednesday, January 23rd. Cantor Fitzgerald reaffirmed a “buy” rating and set a $35.00 price target on shares of Evolus in a research report on Tuesday, April 30th. Stifel Nicolaus initiated coverage on shares of Evolus in a research report on Monday, January 28th. They set a “buy” rating and a $27.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $37.00 price target on shares of Evolus in a research report on Thursday, April 4th. Finally, SunTrust Banks initiated coverage on shares of Evolus in a research report on Wednesday, March 20th. They set a “buy” rating and a $30.00 price target on the stock. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. Evolus has an average rating of “Buy” and a consensus target price of $31.00.
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Recommended Story: Stop Order
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.